Wall Street analysts expect Retrophin Inc (NASDAQ:RTRX) to post earnings of ($0.37) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Retrophin’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.02). Retrophin posted earnings of ($0.68) per share during the same quarter last year, which suggests a positive year over year growth rate of 45.6%. The firm is scheduled to announce its next earnings results on Thursday, November 7th.
According to Zacks, analysts expect that Retrophin will report full-year earnings of ($2.19) per share for the current fiscal year, with EPS estimates ranging from ($3.16) to ($1.66). For the next fiscal year, analysts expect that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($3.41) to ($1.40). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Retrophin.
Retrophin (NASDAQ:RTRX) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.27). Retrophin had a negative net margin of 83.94% and a negative return on equity of 46.04%. The business had revenue of $44.71 million for the quarter, compared to analysts’ expectations of $43.01 million. During the same period last year, the firm earned ($0.25) EPS. The company’s revenue was up 8.2% compared to the same quarter last year.
RTRX traded up $0.24 on Friday, hitting $18.42. The company had a trading volume of 10,297 shares, compared to its average volume of 379,908. The stock’s fifty day simple moving average is $20.30. Retrophin has a 1-year low of $15.55 and a 1-year high of $33.00. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57. The company has a market capitalization of $797.24 million, a PE ratio of -7.27 and a beta of 0.90.
In other Retrophin news, CFO Laura Clague sold 2,500 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $18.25, for a total transaction of $45,625.00. Following the completion of the sale, the chief financial officer now directly owns 14,750 shares in the company, valued at approximately $269,187.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Steve Aselage sold 3,676 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $17.81, for a total transaction of $65,469.56. Following the sale, the director now owns 257,804 shares of the company’s stock, valued at $4,591,489.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,319 shares of company stock worth $244,378. Insiders own 4.32% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in RTRX. Panagora Asset Management Inc. grew its stake in Retrophin by 11.8% in the 2nd quarter. Panagora Asset Management Inc. now owns 454,192 shares of the biopharmaceutical company’s stock worth $9,125,000 after acquiring an additional 47,870 shares in the last quarter. Prudential Financial Inc. boosted its stake in Retrophin by 0.4% in the second quarter. Prudential Financial Inc. now owns 253,099 shares of the biopharmaceutical company’s stock valued at $5,084,000 after acquiring an additional 1,010 shares in the last quarter. Handelsinvest Investeringsforvaltning boosted its stake in Retrophin by 19.6% in the second quarter. Handelsinvest Investeringsforvaltning now owns 80,000 shares of the biopharmaceutical company’s stock valued at $1,607,000 after acquiring an additional 13,084 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Retrophin by 19.6% in the second quarter. JPMorgan Chase & Co. now owns 17,172 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 2,815 shares in the last quarter. Finally, Mckinley Capital Management LLC Delaware acquired a new stake in Retrophin in the second quarter valued at approximately $4,150,000.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Recommended Story: Hedge Funds – How They Work For Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.